ScholarIQanswers from OpenAlex & ORCID
Joel M. Kremer
ResearcherPublications, citations & collaboration network
Joel M. Kremer is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Joel M. Kremer have?
ScholarIQindexed works
Joel M. Kremer has 452 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Joel M. Kremer have?
ScholarIQcitation count
Joel M. Kremer has 39,685 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Joel M. Kremer?
ScholarIQh-index
Joel M. Kremer has an h-index of 94 in OpenAlex.
What is the i10-index of Joel M. Kremer?
ScholarIQi10-index
Joel M. Kremer has an i10-index of 265 in OpenAlex.
What is the ORCID of Joel M. Kremer?
ScholarIQorcid
The ORCID for Joel M. Kremer is on the source record.
What is the OpenAlex record for Joel M. Kremer?
ScholarIQopenalex
The OpenAlex for Joel M. Kremer is on the source record.
What are the most-cited papers on Joel M. Kremer?
ScholarIQmost cited works
2012 Update of the 2008 American College of Rheumatology recommendations for the use of disease‐modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis
Jasvinder A. Singh, Daniel E. Fürst, Aseem Bharat, Jeffrey R. Curtis, Arthur F. Kavanaugh, Joel M. Kremer, Larry W. Moreland, James R. O’Dell, Kevin Winthrop, Timothy Beukelman, S. Louis Bridges, W. Winn Chatham, Harold E. Paulus, María E. Suarez‐Almazor, Claire Bombardier, Maxime Dougados, Dinesh Khanna, Charles M. King, Amye Leong, Eric L. Matteson, John T. Schousboe, Eileen Moynihan, Karen S. Kolba, Archana Jain, Elizabeth R. Volkmann, Harsh Agrawal, Sangmee Bae, Amy S. Mudano, Nivedita M. Patkar, Kenneth G. Saag
IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial
Paul Emery, Edward Keystone, Hans‐Peter Tony, Alain Cantagrel, Ronald van Vollenhoven, Antonio Sánchez, Emma Alecock, J. Lee, Joel M. Kremer
Placebo-Controlled Trial of Tofacitinib Monotherapy in Rheumatoid Arthritis
Roy Fleischmann, Joel M. Kremer, John J. Cush, Hendrik Schulze‐Koops, Carol A. Connell, John Bradley, David Gruben, Gene V. Wallenstein, Samuel H. Zwillich, Keith S. Kanik
Tofacitinib (CP‐690,550) in patients with rheumatoid arthritis receiving methotrexate: Twelve‐month data from a twenty‐four–month phase III randomized radiographic study
Désirée van der Heijde, Yoshiya Tanaka, Roy Fleischmann, Edward Keystone, Joel M. Kremer, Cristiano A. F. Zerbini, Myrna Cardiel, Stanley Cohen, Peter Nash, Yeong Wook Song, Dana Tegzová, Bradley T. Wyman, David Gruben, Birgitta Benda, Gene V. Wallenstein, Sriram Krishnaswami, Samuel H. Zwillich, John Bradley, Carol A. Connell, and the ORAL Scan Investigators
The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double‐blind, placebo‐controlled phase IIa trial of three dosage levels of CP‐690,550 versus placebo
Joel M. Kremer, Bradley J. Bloom, Ferdinand C. Breedveld, John Coombs, Mark P. Fletcher, David Gruben, Sriram Krishnaswami, Rubén Burgos‐Vargas, Bethanie Wilkinson, Cristiano A. F. Zerbini, Samuel H. Zwillich